Featured Research

from universities, journals, and other organizations

Boston Hospitals Report Early Results Of Endostatin Clinical Trial

Date:
November 13, 2000
Source:
Dana-Farber Cancer Institute
Summary:
Clinical researchers at Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center today presented preliminary information from their Phase I clinical trial of Endostatin™ Protein, an angiogenesis inhibitor that seeks to reduce tumors by cutting off their blood supply.

BOSTON -- Clinical researchers at Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center today presented preliminary information from their Phase I clinical trial of Endostatin™ Protein, an angiogenesis inhibitor that seeks to reduce tumors by cutting off their blood supply.

Related Articles


Early results from 19 patients treated in the Boston clinical trial were reported in Amsterdam at the Symposium on New Drugs in Cancer Therapy sponsored by the National Cancer Institute, European Organization for Research and the Treatment of Cancer and American Association of Cancer Research. Results from patients treated in Texas and Wisconsin were also reported at the conference being held November 7 - 10.

"Endostatin is safe and well-tolerated in high doses without any evidence of toxicity," said Donald Kufe, MD, principal investigator of the Harvard hospital clinical trial. "Extended periods of stable disease and minor responses have been demonstrated; however, these are early results and further study is needed to determine just how effective this therapy will be over time."

The Boston hospitals were the first to begin testing of the Endostatin Protein in patients in fall 1999. Since then, 19 patients have been enrolled in the Boston portion of this Phase I trial. Two patients in Boston are currently receiving treatment and twelve patients were taken off the study due to disease progression. The remaining patients voluntarily withdrew from the study.

Of the patients being reported on in Europe, four were diagnosed with breast cancer, three with lung cancer, three with colon cancer, two with pancreatic cancer, two with neuro-endocrine tumors, two with sarcoma, and three with other forms of cancer.

"It is too early to assess the clinical significance of Endostatin's effectiveness based on this preliminary data," said Kufe. "The study was designed to measure Endostatin's safety, not its efficacy. We were pleased to see no major side effects at all dose levels, but further research is needed to determine which dose and infusion schedule are most appropriate for this therapy."

The Boston data being presented comes primarily from the first five groups of patients infused in 28-day cycles in what is known as a "dose escalation" trial. Groups of three patients each were enrolled and infused at 15, 30, 60, 120, and 240mg/m2 (milligrams per meter squared-a ratio of drug to body mass) dose levels.

Additional patients are being treated at either 60 or 240mg/m2 dose levels to obtain further clinical data on Endostatin. These patients will be given Endostatin daily for two months and then moved to a continuous infusion regimen.

"Continuous infusion of Endostatin provides us with the ability to maintain constant levels of the drug in patients rather than the 'peaks and troughs' observed with the current regimen," said Kufe. "We will look for any differences resulting from this approach."

Boston hospitals are currently selecting the final patients into the Phase I trial from their original patient database that opened in fall 1999 and closed to new patient enrollment in July 2000. Patients who enrolled in this database will be contacted if they have been selected for the final slots in the trial. No information is available at this time about future Endostatin clinical trials at Boston hospitals.

Data from the ongoing study at Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center and the other two sites will be used to determine appropriate treatment regimens and doses for future studies.

###

Information regarding other clinical trials can be found on the web sites for Dana-Farber, Mass. General, Brigham & Women and Beth Israel Deaconess.

The Phase I study is being conducted by Dana-Farber/Partners CancerCare -- a collaboration of Dana-Farber Cancer Institute, Brigham and Women's Hospital and Massachusetts General Hospital -- in conjunction with Beth Israel Deaconess Medical Center, a member of the CareGroup healthcare system. The sponsor for this trial is EntreMed, Inc., Rockville, Maryland.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Boston Hospitals Report Early Results Of Endostatin Clinical Trial." ScienceDaily. ScienceDaily, 13 November 2000. <www.sciencedaily.com/releases/2000/11/001110071759.htm>.
Dana-Farber Cancer Institute. (2000, November 13). Boston Hospitals Report Early Results Of Endostatin Clinical Trial. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2000/11/001110071759.htm
Dana-Farber Cancer Institute. "Boston Hospitals Report Early Results Of Endostatin Clinical Trial." ScienceDaily. www.sciencedaily.com/releases/2000/11/001110071759.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
Dads-To-Be Also Experience Hormone Changes During Pregnancy

Dads-To-Be Also Experience Hormone Changes During Pregnancy

Newsy (Dec. 18, 2014) A study from University of Michigan researchers found that expectant fathers see a decrease in testosterone as the baby's birth draws near. Video provided by Newsy
Powered by NewsLook.com
Prenatal Exposure To Pollution Might Increase Autism Risk

Prenatal Exposure To Pollution Might Increase Autism Risk

Newsy (Dec. 18, 2014) Harvard researchers found children whose mothers were exposed to high pollution levels in the third trimester were twice as likely to develop autism. Video provided by Newsy
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins